Abstract
The treatment of systemic hypertension (HTN) in patients with Aortic stenosis (AS) requires a careful balance of lowering the systemic blood pressure without compromising vital organ perfusion and worsening of the symptoms of AS. Treatment of systemic HTN is beneficial because the combination of HTN and AS provides additional overload to the left ventricle. This leads to secondary Left ventricular hypertrophy (LVH), which has been shown to increase cardiovascular risks and mortality and thus early presentation of symptoms of AS. Additionally, presence of HTN may affect the accurate assessment of AS. Different treatment options are available, however no specific treatment guidelines have been established for patients with concomitant AS and HTN. Improved control of HTN is the key to prevent symptom progression and inadvertent early surgery. Angiotensin converting enzyme inhibitors (ACEi) and Angiotensin receptor blockers (ARB) appear to be beneficial. Reassessment of the aortic valve by echocardiography is recommended after HTN is well controlled before deciding on aortic valve replacement (AVR).
Keywords: Aortic stenosis, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, cardiovascular risks, hypertension, pharmacological therapy.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Systemic Hypertension in Patients with Aortic Stenosis: Clinical Implications and Principles of Pharmacological Therapy
Volume: 13 Issue: 1
Author(s): Sucheta Gosavi, Rahul Channa and Debabrata Mukherjee
Affiliation:
Keywords: Aortic stenosis, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, cardiovascular risks, hypertension, pharmacological therapy.
Abstract: The treatment of systemic hypertension (HTN) in patients with Aortic stenosis (AS) requires a careful balance of lowering the systemic blood pressure without compromising vital organ perfusion and worsening of the symptoms of AS. Treatment of systemic HTN is beneficial because the combination of HTN and AS provides additional overload to the left ventricle. This leads to secondary Left ventricular hypertrophy (LVH), which has been shown to increase cardiovascular risks and mortality and thus early presentation of symptoms of AS. Additionally, presence of HTN may affect the accurate assessment of AS. Different treatment options are available, however no specific treatment guidelines have been established for patients with concomitant AS and HTN. Improved control of HTN is the key to prevent symptom progression and inadvertent early surgery. Angiotensin converting enzyme inhibitors (ACEi) and Angiotensin receptor blockers (ARB) appear to be beneficial. Reassessment of the aortic valve by echocardiography is recommended after HTN is well controlled before deciding on aortic valve replacement (AVR).
Export Options
About this article
Cite this article as:
Gosavi Sucheta, Channa Rahul and Mukherjee Debabrata, Systemic Hypertension in Patients with Aortic Stenosis: Clinical Implications and Principles of Pharmacological Therapy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (1) . https://dx.doi.org/10.2174/187152571301150730114814
DOI https://dx.doi.org/10.2174/187152571301150730114814 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Management of Traumatic Rupture of the Descending Thoracic Aorta
Current Cardiology Reviews Diagnostic and Therapeutic Potentials of microRNAs in Heart Failure
Current Topics in Medicinal Chemistry Biological Activities of Three Extracts from Artedia squamata: A Study on Antioxidant and Enzyme Inhibitory Potential
Current Bioactive Compounds Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Targets Involved in Cardioprotection by the Non-Anesthetic Noble Gas Helium
Current Drug Targets Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Study of Hypolipidemic and Antioxidant Activities of Anvillea radiata Coss & Durieu in Diabetic Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Prediction Models and Scores in Pulmonary Hypertension: A Review
Current Pharmaceutical Design Association Between Anemia and Dementia: A Nationwide, Populationbased Cohort Study in Taiwan
Current Alzheimer Research Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders
Current Medicinal Chemistry The Possible Impact of Hyperuricemia on Serum Soluble Receptor for Advanced Glycation end Products (sRAGE) Levels in Teenagers: A Case Control Study
Current Pharmaceutical Design Lower Frequency of co-Morbid Medical Disorders Related to Poor Impulse Control in Parkinson’s than Alzheimer’s Disease
Current Aging Science Effect of the Interaction Between Hypertension and Cerebral White Matter Changes on the Progression of Alzheimer Disease
Current Alzheimer Research Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools
Protein & Peptide Letters Cardiovascular Toxicity of Cyclooxygenase Inhibitors and Promising Natur a l Substitutes
Current Pharmaceutical Design Gender Differences in Aminoglycoside Induced Nephrotoxicity: A Prospective, Hospital - Based Study
Current Clinical Pharmacology Systematic Understanding of the Mechanisms of <i>Flos Chrysanthemi Indici</i>-mediated Effects on Hypertension <i>via</i> Computational Target Fishing
Combinatorial Chemistry & High Throughput Screening Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Preface
Current Drug Targets - Cardiovascular & Hematological Disorders Formulation Development of Metoprolol Succinate and Hydrochlorothiazide Compression Coated Tablets
Current Drug Delivery